WH-4-023 - CAS 837422-57-8
Catalog number: 837422-57-8
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
WH-4-023 is a potent and selective dual Lck/Src inhibitor with IC50 of 2 nM/6 nM for Lck and Src kinase respectively. The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and NK cells.
Solid powder
WH-4-023; WH4-023; WH 4-023; WH-4023; WH 4023; WH4023;
Canonical SMILES:
Current Developer:
Amgen Inc
1.Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
Serafin V;Capuzzo G;Milani G;Minuzzo SA;Pinazza M;Bortolozzi R;Bresolin S;Porcù E;Frasson C;Indraccolo S;Basso G;Accordi B Blood. 2017 Dec 21;130(25):2750-2761. doi: 10.1182/blood-2017-05-784603. Epub 2017 Nov 3.
Pediatric T-acute lymphoblastic leukemia (T-ALL) patients often display resistance to glucocorticoid (GC) treatment. These patients, classified as prednisone poor responders (PPR), have poorer outcome than do the other pediatric T-ALL patients receiving a high-risk adapted therapy. Because glucocorticoids are administered to ALL patients during all the different phases of therapy, GC resistance represents an important challenge to improving the outcome for these patients. Mechanisms underlying resistance are not yet fully unraveled; thus our research focused on the identification of deregulated signaling pathways to point out new targeted approaches. We first identified, by reverse-phase protein arrays, the lymphocyte cell-specific protein-tyrosine kinase (LCK) as aberrantly activated in PPR patients. We showed that LCK inhibitors, such as dasatinib, bosutinib, nintedanib, and WH-4-023, are able to induce cell death in GC-resistant T-ALL cells, and remarkably, cotreatment with dexamethasone is able to reverse GC resistance, even at therapeutic drug concentrations. This was confirmed by specific ;LCK; gene silencing and ex vivo combined treatment of cells from PPR patient-derived xenografts.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Src Products

CAS 172889-26-8 PP1

(CAS: 172889-26-8)

PP1 is a potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases. It inhibits p56lck (IC50 = 5 nM), p59fynT (...

CAS 944795-06-6 Lck inhibitor 2

Lck inhibitor 2
(CAS: 944795-06-6)

Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. It inhibited 48 kinases with control less than 1...

CAS 1435934-25-0 A 419259 trihydrochloride

A 419259 trihydrochloride
(CAS: 1435934-25-0)

Potent Hck inhibitor (IC50 = 0.43 nM). Also inhibits other Src family kinases (SFKs). Suppresses proliferation and induces apoptosis in CML cell lines including...

(CAS: 1162656-22-5)

MCB-613 is a potent steroid receptor coactivator (SRC) stimulator.

CAS 869748-10-7 A-770041

(CAS: 869748-10-7)

A-770041 is an selective and orally bioavailable pyrazolo[3,4-d]pyrimidine exhibiting selectivity for Lck compared with previously reported compounds. It is 300...

CAS 897016-82-9 KX2-391

(CAS: 897016-82-9)

KX2-391 is an orally bioavailable small molecule Src kinase inhibitor with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to t...

CAS 172889-27-9 PP2

(CAS: 172889-27-9)

PP2 is a potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases. It inhibits p56lck (IC50 = 4 nM), p59fynT (...

(CAS: 1914078-41-3)

eCF506 is a potent and highl selective inhibitor towards Src tyrosine kinase with a 1000-fold selectivity over ABL. eCF506 inhibits SRC at subnanomolar concentr...

Chemical Structure

CAS 837422-57-8 WH-4-023

Quick Inquiry

Verification code

Featured Items